“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin’s Brazilian subsidiary, Medquímica was acquired in 2015 for its strong manufacturing platform and its efficient substitution generic commercial structure, with the goal to position Lupin in Brazil. It is the 5th largest company in volumes in Brazil and is ranked 14th in value amongst its Indian peers. Medquímica grew 3.4% in value and 8.7% in units in FY2019. A total of 15 new products were filed with ANVISA and received 10 new MA during FY2019.
